Akorn Receives FDA Approval for Ephedrine Sulfate Injection, USP
March 02 2017 - 8:25AM
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generics
pharmaceutical company, today announced that it has received
approval from the U.S. Food and Drug Administration (FDA) for its
New Drug Application (NDA) for Ephedrine Sulfate Injection, USP 50
mg/mL in 1 mL single dose ampule. Ephedrine sulfate injection
is indicated for the treatment of clinically important hypotension
occurring in the setting of anesthesia.
About AkornAkorn, Inc. is a specialty generic
pharmaceutical company engaged in the development, manufacture and
marketing of multisource and branded pharmaceuticals. Akorn has
manufacturing facilities located in Decatur, Illinois; Somerset,
New Jersey; Amityville, New York; Hettlingen, Switzerland and
Paonta Sahib, India that manufacture ophthalmic, injectable and
specialty sterile and non-sterile pharmaceuticals. Additional
information is available on Akorn’s website at www.akorn.com.
Investors/Media:
Stephanie Carrington
ICR, Inc.
(646) 277-1282
Stephanie.carrington@icrinc.com
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Apr 2023 to Apr 2024